
==== Front
BMJ Open
BMJ Open
bmjopen
bmjopen
BMJ Open
2044-6055
BMJ Publishing Group BMA House, Tavistock Square, London, WC1H 9JR

39209495
10.1136/bmjopen-2023-080597
bmjopen-2023-080597
Protocol
Cardiovascular Medicine
1683
1506
High-exchange ULTrafiltration to enhance recovery after paediatric cardiac surgery (ULTRA): study protocol for a Canadian double-blinded randomised controlled trial
https://twitter.com/jbierer
http://orcid.org/0000-0002-4579-5674
Bierer Joel 1Joel.Bierer@nshealth.ca

Stanzel Roger 2Roger.Stanzel@nshealth.ca

Henderson Mark 2MarkJ.Henderson@nshealth.ca

Krmpotic Kristina 3kristina.krmpotic@iwk.nshealth.ca

Andreou Pantelis 4pantelis.andreou@dal.ca

Marshall Jean S. 5Jean.Marshall@dal.ca

Sapp John 6John.Sapp@nshealth.ca

Horne David 1David.Horne@iwk.nshealth.ca

1 Division of Cardiac Surgery, Dalhousie University, Halifax, Nova Scotia, Canada
2 Department of Clinical Perfusion, Nova Scotia Health Authority, Halifax, Nova Scotia, Canada
3 Department of Critical Care, Dalhousie University, Halifax, Nova Scotia, Canada
4 Department of Community Health and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada
5 Department of Microbiology & Immunology, Dalhousie University, Halifax, Nova Scotia, Canada
6 Division of Cardiology, Dalhousie University, Halifax, Nova Scotia, Canada
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

None declared.

DrJoelBierer; Joel.Bierer@nshealth.ca
2024
28 8 2024
14 8 e08059705 10 2023
09 8 2024
Copyright © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
2024
https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

Abstract

Introduction

Surgical repair is the standard of care for most infants and children with congenital heart disease. Cardiopulmonary bypass (CPB) is required to facilitate these operations but elicits a systemic inflammatory response, leading to postoperative organ dysfunction, morbidity and prolonged recovery after the surgery. Subzero-balance ultrafiltration (SBUF) has been shown to extract proinflammatory cytokines continuously throughout the CPB exposure. We hypothesize that a high-exchange SBUF (H-SBUF) will have a clinically relevant anti-inflammatory effect compared with a low-exchange SBUF (L-SBUF).

Methods and analysis

The ULTrafiltration to enhance Recovery After paediatric cardiac surgery (ULTRA) trial is a randomised, double-blind, parallel-group randomised trial conducted in a single paediatric cardiac surgery centre. Ninety-six patients less than 15 kg undergoing cardiac surgery with CPB will be randomly assigned to H-SBUF during CPB or L-SBUF during CPB in a 1:1 ratio with stratification by The Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery (STAT) score 1 and STAT score 2–5. The primary outcome is peak postoperative vasoactive-ventilation-renal score. Time series and peak values of vasoactive-ventilation renal score, vasoactive-inotrope score, ventilation index and oxygenation index will be collected. Secondary clinical outcomes include acute kidney injury, ventilator-free days, inotrope-free days, low cardiac output syndrome, mechanical circulatory support, intensive care unit length of stay and operative mortality. Secondary biomarker data include cytokine, chemokine and complement factor concentrations at baseline before CPB, at the end of CPB exposure and 24 hours following CPB. Analyses will be conducted on an intention-to-treat principle.

Ethics and dissemination

The study has ethics approval (#1024932 dated August 31, 2021) and enrolment commenced in September 2021. The primary manuscript and any subsequent analyses will be submitted for peer-reviewed publication.

Trial registration number

NCT04920643.

paediatric cardiothoracic surgery
clinical trial
paediatric intensive & critical care
immunology
http://dx.doi.org/10.13039/501100005785 Faculty of Medicine, Dalhousie University Department of Surgery Seed Grant http://dx.doi.org/10.13039/100007670 Dalhousie Medical Research Foundation Equipment Grant http://dx.doi.org/10.13039/501100020170 Research Nova Scotia Scotia Scholar Doctoral Award http://dx.doi.org/10.13039/501100000028 Institute of Circulatory and Respiratory Health Doctoral Award #181479 http://dx.doi.org/10.13039/501100002330 Nova Scotia Department of Health and Wellness Clinician Investigator Program
==== Body
pmcSTRENGTHS AND LIMITATIONS OF THIS STUDY

The ULTrafiltration to enhance Recovery After paediatric cardiac surgery (ULTRA) trial will directly assess the anti-inflammatory effect of continuous ultrafiltration exchange rate in a randomised and double-blinded fashion with broad inclusion criteria.

ULTRA will collect and analyse clinical outcomes, clinical score times series and comprehensive inflammatory mediator biomarker data through the perioperative course of children undergoing congenital heart surgery.

The high-exchange subzero balance ultrafiltration intervention aims to reduce morbidity and critical care requirements following paediatric cardiac surgery, which is important to patients, their families and healthcare institutions.

Relative limitations of the study are power, patient population heterogeneity and generalisability due to single-centre design. Notwithstanding, the trial is powered to detect a significant difference in the validated clinical score primary outcome as a surrogate to other important clinical results.

Background

Congenital heart disease occurs in 1% of all live births, and approximately one-quarter of these individuals will require surgical intervention in the first year of life.1 Although there has been a marked reduction in operative mortality over the last three decades—due to significant advances in surgical technique, myocardial protection, intensive care management and mechanical circulatory support—cardiopulmonary bypass (CPB)-associated inflammation continues to negatively impact recovery. Exposure to the non-endothelialised circuit instantly triggers the complement system, contact activation, coagulation cascade and acute-phase reactants.26 The sterile innate response features circulating proinflammatory mediators, including complement anaphylatoxins (C3a and C5a), cytokines (tumour necrosis factor (TNF), IL-1α, IL-1β and IL-6) and chemokines (CXCL-8), which stimulate endothelial leak, neutrophil recruitment, translocation and ultimately tissue injury.257 Clinically, CPB-associated inflammation manifests as a systemic inflammatory response syndrome with cardiac, pulmonary, and vasomotor dysfunction yielding hours or days of intensive care requirements in the postoperative period and potentially secondary organ dysfunction.257 8 Unfortunately, there are no proven treatments to manage this syndrome, which negatively affects these vulnerable patients, their families and have substantial healthcare costs.1 8

Ultrafiltration has been used during paediatric cardiac surgery since the 1990s, primarily to remove excess volume and prevent tissue oedema.9 Shortly after its implementation, due to observations of improved haemodynamic parameters and cardiopulmonary function, the therapy was hypothesized to extract proinflammatory substances and myocardial depressants from the patient’s circulation.1012 Currently, 22 inflammatory mediators are known to be extracted by this modality throughout CPB, including C3a, C5a, TNF, IL-1β, IL-6, CXCL-8 and others.8 13 C3a and C5a appear to be the most relevant to clinical inflammation and, importantly, ultrafiltration effectively extracts these factors with sieving coefficients of 1019% and 46%, respectively.13 To maximise the extraction of proinflammatory mediators during CPB, we have designed an ultrafiltration protocol—subzero balance ultrafiltration (SBUF)—that facilitates continuous therapy throughout the entire CPB time.14 In theory, a high-exchange rate of SBUF (H-SBUF) will extract more proinflammatory mediators from the circulation and dampen the systemic inflammatory response relative to a low-exchange SBUF (L-SBUF), thereby ameliorating the clinical sequelae of CPB-associated inflammation. Ultrafiltration during paediatric cardiac surgery is universal, with 97% of global centres using the therapy during CPB, however, protocols can vary widely.8 15 Particularly, there is no standard rate of effluent removal, and both the low and high-exchange therapies in this trial are within the range of accepted practices in the published literature.8

A validated clinical score, peak postoperative vasoactive-ventilation-renal score (VVR), is the primary outcome of this trial.16 The score directly represents the cardiopulmonary, vasomotor, renal and medical stability of the patient in the early postoperative period and is a robust predictor of ventilation time and intensive care unit length of stay.16 Therefore, peak VVR, along with key secondary clinical outcomes of acute renal injury, low cardiac output syndrome, inotrope-free days, ventilator-free days, along with perioperative inflammation mediator biomarkers, will directly assess the anti-inflammatory efficacy of H-SBUF.17 18

ULTrafiltration to enhance Recovery After paediatric cardiac surgery (ULTRA) is a 1:1 allocation parallel-group, double-blinded, superiority trial designed to test the hypothesis that, in paediatric patients less than 15 kg undergoing cardiac surgery for congenital heart disease utilising CPB, H-SBUF will reduce peak postoperative VVR relative to L-SBUF.

Methods

Study design

The high-exchange ULTRA trial is a 96-patient, single-centre, double-blinded, randomised controlled trial conducted at the academic IWK Health Centre, Nova Scotia, Canada. ULTRA is registered on clinicaltrial.gov and follows a prespecified protocol reported here. This protocol is reported following Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines (online supplemental file 1), and the trial will be reported following Consolidated Standards of Reporting Trials (CONSORT) guidelines.19 20 Patient enrolment began in September 2021 and is expected to complete in June 2025.

Patient population

The study population will consist of neonatal, infant and child patients with weight between 2.5 and 15.0 kg undergoing cardiac surgery with CPB. Patients undergoing Fontan operation will be enrolled up to 18.0 kg. Exclusion from participation is by absence of informed written consent, isolated secundum atrial septal defect, severe hepatic disease, severe chronic renal disease, severe hematologic abnormality, genetic syndrome with severe multiorgan abnormalities, severe immunodeficiency syndrome and preoperative mechanical circulatory support.

Randomisation

Patients are randomised 1:1 to either H-SBUF or L-SBUF using permuted block randomisation, consisting of randomly permuted block sizes 2 and 4 and stratified by two risk groups defined by the updated 2020 Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery (STS-EACTS STAT) score.21 The first is a low-risk group defined as STAT=1, and the high-risk group defined as STAT=2–5. This stratification is important as our pilot study revealed these two groups to have significantly different values of peak VVR (the primary outcome of ULTRA), and increasing STAT score is known to have significant implications on morbidity and mortality following children’s heart surgery.21 22 The randomisation sequence was uploaded to Research Electronic Data Capture (REDCap) for administration.23 Randomisation occurs at the preoperative surgical team briefing on the day of operation.

Blinding

ULTRA is a double-blinded trial. Patients, their families, surgeon, anaesthetist, critical care physician, cardiologist, nursing, outcome assessor, research coordinator and statistician are blinded to the assigned treatment group. Only the perfusionists, who execute the randomisation order on REDCap and administer the ultrafiltration treatments, are privy to the treatment allocation. The perfusionist has no other role in the ULTRA study and does not participate in outcome assessment or statistical analysis. Additionally, the infusion pumps and ultrafiltration effluent reservoir are masked from the operating room team using a physical barrier to prevent inadvertent unblinding of the surgical team. Perfusion and ultrafiltration data are recorded by perfusionists and stored in a locked datasheet within the database.

Study treatment

SBUF-simple modified ultrafiltration (SMUF) technique during paediatric CPB has been previously published.14 Infusion pumps allow for the precise management of ultrafiltration effluent removal and physiologic replacement during SBUF, which facilitates both high and low-exchange treatments within the same CPB circuit. The treatment arm of the trial consists of H-SBUF administered throughout the entire CPB time, with effluent extraction of 60 mL/kg/hour and physiologic crystalloid volume replacement of 55 mL/kg/hour, yielding a net negative 5 mL/kg/hour. The control arm of the trail is L-SBUF administered throughout the entire CPB time, with effluent extraction of 6 mL/kg/hour and physiologic crystalloid volume replacement of 1 mL/kg/hour yielding net negative 5 mL/kg/hour. Both groups receive standard-of-care perfusion and ultrafiltration techniques, including buffered preparation of sanguineous prime, conventional ultrafiltration used to immediately remove cardioplegia or surgical field irrigation and simple modified ultrafiltration (SMUF) after the cessation of CPB.14 24 Importantly, this trial is designed to test the impact of continuous ultrafiltration rate while controlling for differences in volume balances between groups. Postoperative care is administered to meet best practices by the institution’s blinded multidisciplinary team.

Study outcomes

The primary outcome is peak VVR in the postoperative period. Along with VVR, vasoactive inotrope score, ventilation index and oxygenation index are defined in table 1 and will be collected in a prespecified time series depicted in figure 1.162527 The peak clinical score is the single highest measurement for each score collected in the standardised time series. Secondary clinical outcomes—including cardiac, pulmonary, renal morbidities and critical care requirements—as well as inflammatory mediator biomarker data are outlined in table 2. Outcomes collected represent a range of validated clinical and biomarker outcomes to evaluate the efficacy of H-SBUF.

Figure 1 Trial longitudinal data collection. CPB, cardiopulmonary bypass; ICU, intensive care unit; OI, oxygenation index; VI, ventilation index; VIS, vasoactive inotrope score; VVR, ventilation-vasoactive-renal score.

Table 1 Clinical score calculations

VVR	VIS+VI + (dCR×10)dCR = ∆ in creatinine from pre-op to post-op (mg/dL)	
VIS	dopamine (μg/kg/min) + dobutamine (μg/kg/min) + 100 x epinephrine (μg/kg/min) + 10 x milrinone (μg/kg/min) +10 000 x vasopressin (U/kg/min) + 100 x norepinephrine (μg/kg/min)	
VI	respiratory rate × (peak inspiratory pressure – peak end-expiratory pressure) × (PaCO2)/1000)	
OI	mean airway pressure×fiO2 × (100/PaO2)	
fiO2fraction of inspired oxygenOIoxygenation indexPaO2arterial partial pressure of oxygenVIventilation indexVISvasoactive inotrope scoreVVRventilation-vasoactive-renal score

Table 2 Study outcomes

Type	Outcome	Definition	
Primary outcome	Peak VVR	Highest value collected in postoperative time series.

Peak VVR for patients with postoperative mechanical extra-corporeal membrane oxygenation will be the sum of calculated peak VVR+50.

	
Clinical scores	VVR, VIS, VI, OITime series	Clinical score calculated at post-sternotomy baseline, post-CPB—0 hours, −12 to –24, −36 to –48, −72 to –96, −120 hours as well as ICU admission.

	
Peak VIS	Highest value collected in postoperative time series.

Peak VIS for patients with post-operative mechanical extra-corporeal membrane oxygenation will be the sum of calculated peak VIS+30.

	
Peak VI	Highest value collected in postoperative time series.

Peak VI for patients with postoperative mechanical extra-corporeal membrane oxygenation will be the sum of calculated peak VI+20.

	
Peak OI	Highest value collected in postoperative time series.

Peak OI for patients with postoperative mechanical extra-corporeal membrane oxygenation will be the sum of calculated peak OI+10.

	
Clinical outcomes	Ventilation time	Measured in days from ICU admission time to first hour after extubation.

Ventilation time following re-intubation during the primary hospitalisation will be included.

A value of 28 days is assigned for mortalities, if actual ventilation time is less.

	
Ventilator-free days	Number of ventilation-free days in the first 28 postoperative days.

Calculated by 28—ventilation time in days.

A value of 0 is assigned for mortalities.

	
Prolonged intubation	Ventilator requirements for more than 7 days following ICU admission.

	
Inotrope time	Measured in days from ICU admission time to first hour after successful inotrope or vasopressor cessation.

Re-initiation of inotrope or vasopressor during the primary hospitalisation will be included.

A value of 28 days is assigned for mortalities, if actual inotrope time is less.

	
Inotrope-free days	Number of inotrope-free days in the first 28 postoperative days.

Calculated by 28—inotrope time in days.

A value of 0 is assigned for mortalities.

	
Inotropic dependence	VIS at post-CPB-48 hours equal to or greater than VIS at ICU admission.

	
Low cardiac output syndrome	Defined by any one of the following within the first 72 postoperative hours:

Lactate>4 mM with oxygen extraction>35% (SaO2 – ScvO2/SaO2)

VIS>15.0 with oxygen extraction>35% (SaO2 – ScvO2/SaO2)

Mechanical circulatory support requirement

	
Vasoplegic shock	Defined by any one of the following with the first 72 postoperative hours:

Lactate>4 mM with oxygen extraction<25% (SaO2 – ScvO2/SaO2)

VIS>15.0 with oxygen extraction<25% (SaO2 – ScvO2/SaO2)

	
Acute kidney injury	KDIGO paediatric criteria graded 1, 2 or 3.

	
Bleeding complications	Chest tube output and postoperative transfusion requirements.

	
Loop diuretic use	Total loop diuretic (mg/kg), measured in oral furosemide equivalents, during the first 7 postoperative days.

	
Clinical composite outcome	Inotrope dependence, mechanical circulatory support, acute kidney injury KDIGO grade 2 or 3, prolonged intubation and operative mortality.

	
ICU LOS	Measured in days from ICU admission time to time of final discharge checklist criteria completed. (See online supplement for discharge criteria).

A value of 30 days is assigned for mortalities, if actual ICU LOS is less.

	
	Hospital LOS	Measured in days from ICU admission time to time of hospital discharge.

A value of 60 days is assigned for mortalities, if actual hospital LOS is less.

	
Laboratory values	CBC, ABG, Cr, CRP, haptoglobin	Measured at baseline and in postoperative period.

	
Inflammatory biomarker	Cytokine, chemokine and complement	Measured at baseline, post-CPB-0 hours and post-CPB-24 hours.

	
ABG, arterial blood gas; CBC, complete blood count; CrcreatinineCRP, C reactive protein; ICU, intensive care unit; KDIGO, kidney disease improving global outcomes; LOS, length of stay; OI, oxygenation index; SaO2, arterial haemoglobin oxygen saturation; ScvO2, central venous haemoglobin oxygen saturation; VI, ventilation index; VIS, vasoactive inotrope score; VVR, ventilation-vasoactive-renal score

Sample size

The primary outcome of ULTRA is the peak postoperative VVR score. The sample size calculation was based on a minimal clinically important relative reduction in the primary outcome of 25%. This threshold was identified by consultation with clinical experts and represents a significant improvement in cardiopulmonary and vasomotor function. A two-way analysis of variance (ANOVA)which considered the stratification by STAT score (STAT 1 and STAT 2–5) with alpha=0.05 and beta=0.2. The decision to stratify by surgical risk STAT score was crucial to ensure this variable is balanced for comparison between treatment groups, as STAT score is strongly correlated with morbidity and mortality after paediatric cardiac surgery.21 The sample size calculation used peak VVR data from the pilot study for patients that matched ULTRA’s inclusion criteria. According to these parameters, 48 patients in each group are required, yielding a total of 96 patients.

Data collection and management

JB, blinded to randomised treatment allocation, prospectively collects prespecified clinical outcomes on a primary hard copy template and biologic samples for biomarker analysis. Follow-up is until hospital discharge or death. The data are transferred and managed on REDCap electronic data capture tools hosted at the IWK Health Centre.23 Data records are deidentified, participating patients will be assigned an anonymising code with the key stored separately and securely.

Inflammatory mediator analysis

Arterial blood samples will be collected at baseline (after anaesthesia induction and sternotomy but before CPB-initiation), post-CPB-0 hours (after weaning of CPB and conclusion of SMUF) and post-CPB-24 hours. Samples are collected in EDTA tubes, processed to platelet-free plasma and flash-frozen to be stored at −80°C. Complement factors (C3, C3a, C3b, C5, C5a, among other), cytokines (IL-1, IL1-Ra, IL-6, IL-10, TNF, and others), chemokines (CXCL-8) and other relevant mediators will be quantified by multiplex immunoassay. All samples will be analysed simultaneously after patient enrolment is completed by JB.

Statistical analyses

There will be no interim analyses. The final analysis will follow the intention-to-treat principle and be completed in a blinded fashion by PA who does not participate in data collection or outcome assessment. If there are deviations from the assigned treatment, an as-treated analysis will be considered to supplement the intention-to-treat results. Descriptive statistics will describe the characteristics of both treatment arms. Clinical and biomarker outcomes will be assessed for normalcy by quantile-quantile plots and Shapiro-Wilk test. Normally distributed outcomes will be compared using an independent t-test, and non-normally disturbed outcomes will be compared using the Mann-Whitney U test. Dichotomous outcomes will be compared by either Pearson’s χ2 test or Fisher’s exact test. Time-to-event analyses forlow cardiac output syndrome (LCOS), vasoplegic shock and clinical composite endpoint will be conducted by Kaplan-Meier or proportional hazard regression. Longitudinal time series analyses (clinical score and inflammatory mediator) will compare the two treatment groups at each time point individually and together through generalised linear mixed models. Statistical significance is α=0.05.

There will be a subgroup analysis based on the STS-EACTS STAT score 1 and 2–5 in accordance with the stratification method. There will be exploratory subgroup analyses based on sex (male and female) and CPB prime (sanguineous and asanguineous). The CPB prime subgroups, which also equates to those below (sanguineous) and above 10 kg (asanguineous) at our institution, are of particular interest as this approach eliminates significant sources of patient heterogeneity due to age, weight, corresponding congenital heart disease and operations as well as CPB prime exposures.

Data Safety Monitoring Board

The Data Safety Monitoring Board (DSMB) consists of a Paediatric Cardiologist, an Intensivist and a Perfusionist at the IWK Health Centre, none of whom is study investigators. The DSMB will meet to review blinded results at 25%, 50%, 75% and 100% enrolment. Each report will feature enrolment progression, perfusion complication, acute kidney injury, mechanical circulatory support and operative mortality. The DSMB can request an unblinding of the results if there is a substantial differential in safety outcomes between the two groups. The DSMB will recommend to the steering committee that the trial continue, be modified, or terminated following each analysis. The recommendation letter will be submitted to the Research Ethics Board (REB) as part of the study protocol. The purpose of the DSMB is to monitor the safety and proceedings for the ULTRA trial, independent of the investigators.

Serious adverse event reporting

Paediatric cardiac surgery carries substantial risk as many patients can experience morbidities, organ failure and even mortality despite optimal care. Complications or events that are part of the congenital heart disease natural history or convalescence following cardiac surgery will not be reported as serious adverse events. All adverse events which are potentially or causally related to the study SBUF intervention will be reported to the REB. Specific events primarily revolve around perfusion complications such as air embolism, pump thrombosis, and severe haemolysis; these are extraordinarily rare in modern practice.

Study organisation

The study leadership consists of a steering committee and an independent DSMB. The steering committee comprises the principal investigator and investigators with expertise in all aspects of the translational randomised trial, including paediatric cardiac surgery, paediatric clinical perfusion, paediatric critical care, immunology, statistics, and randomised trial methods. The steering committee was responsible for the design and maintenance of the trial.

Ethics

The study will be conducted with protocol and standard operating procedures approved by the REB at the IWK Health Centre (#1024932). Annual renewal of the approval and submission of all four DSMB reports are required. Informed written consent is required by the patient’s substitute decision-maker before enrolment. The consent form and standard operating procedures are part of the IWK Health Centre’s REB approved protocol #1 024 932 dated August 31, 2021. An example of the consent form is seen in online supplemental file 2. Research personnel discuss participation with the substitute decision-maker during preoperative surgical assessment in the outpatient clinic or inpatient ward. Protocol deviations are submitted to the principal investigator and recorded in the patient’s study record. Participant confidentiality is maintained through de-identification methods and secured records.

Dissemination policy

The results of this trial will be disseminated to congenital cardiac care clinicians and researchers through peer-reviewed publication and conference presentations. Authorship will be assessed using criteria from the publisher. In general, the dataset will not be publicly available. Data requests will be considered on a case-by-case basis and in line with the trial’s Research Ethics Board approval.

Patient and public involvement

There was no patient or public involvement in the design of this trial.

supplementary material

10.1136/bmjopen-2023-080597 online supplemental file 1

10.1136/bmjopen-2023-080597 online supplemental file 2

Acknowledgements

The authors would like to thank the children and families for participating in this research as well as the IWK Health Centre Cardiac Surgery, Clinical Perfusion, Anesthesia, Cardiology, Critical Care, and Peri-operative care for facilitating data collection and study procedures.

Review Process File
28 08 2024

Funding: This study received funding from the Canadian Institutes of Health Research (#181479), Dalhousie University Department of Surgery, Dalhousie Medical Research Foundation and Research Nova Scotia. JB receives salary support from the Nova Scotia Ministry of Health through the Dalhousie University Clinician Investigator Program.

Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (https://doi.org/10.1136/bmjopen-2023-080597).

Provenance and peer review: Not commissioned; externally peer-reviewed.

Patient consent for publication: Not applicable.

Patient and public involvement: Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.
==== Refs
References

1 Triedman JK Newburger JW Trends in congenital heart disease Circulation 2016 133 2716 33 10.1161/CIRCULATIONAHA.116.023544 27324366
2 Warren OJ Smith AJ Alexiou C et al The inflammatory response to cardiopulmonary bypass: Part 1—mechanisms of pathogenesis J Cardiothorac Vasc Anesth 2009 23 223 31 10.1053/j.jvca.2008.08.007 18930659
3 Butler J Rocker GM Westaby S Inflammatory response to cardiopulmonary bypass Ann Thorac Surg 1993 55 552 9 10.1016/0003-4975(93)91048-R 8431082
4 Bronicki RA Hall M Cardiopulmonary bypass-induced inflammatory response: Pathophysiology and treatment Pediatr Crit Care Med 2016 17 S272 8 10.1097/PCC.0000000000000759 27490610
5 Paparella D Yau TM Young E Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update Eur J Cardiothorac Surg 2002 21 232 44 10.1016/S1010-7940(01)01099-5 11825729
6 Squiccimarro E Stasi A Lorusso R et al Narrative review of the systemic inflammatory reaction to cardiac surgery and cardiopulmonary bypass Artif Organs 2022 46 568 77 10.1111/aor.14171 35061922
7 Kozik DJ Tweddell JS Characterizing the inflammatory response to cardiopulmonary bypass in children Ann Thorac Surg 2006 81 S2347 54 10.1016/j.athoracsur.2006.02.073 16731102
8 Bierer J Stanzel R Henderson M et al Ultrafiltration in pediatric cardiac surgery review World J Pediatr Congenit Heart Surg 2019 10 778 88 10.1177/2150135119870176 31701831
9 Naik SK Knight A Elliott MJ A successful modification of ultrafiltration for cardiopulmonary bypass in children Perfusion 1991 6 41 50 10.1177/026765919100600106 10149499
10 Andreasson S Göthberg S Berggren H et al Hemofiltration modifies complement activation after extracorporeal circulation in infants Ann Thorac Surg 1993 56 1515 7 10.1016/0003-4975(93)90743-2 8267479
11 Elliott MJ Ultrafiltration and modified ultrafiltration in pediatric open heart operations Ann Thorac Surg 1993 56 1518 22 10.1016/0003-4975(93)90744-3 8267480
12 Saatvedt K Lindberg H Geiran OR et al Ultrafiltration after cardiopulmonary bypass in children: effects on hemodynamics, cytokines and complement Cardiovasc Res 1996 31 596 602 10.1016/S0008-6363(95)00237-5 8689651
13 Bierer J Stanzel R Henderson M et al Novel inflammatory mediator profile observed during pediatric heart surgery with cardiopulmonary bypass and continuous ultrafiltration J Transl Med 2023 21 439 439 10.1186/s12967-023-04255-8 37408044
14 Bierer J Henderson M Stanzel R et al Subzero balance - simple modified ultrafiltration (SBUF-SMUF) technique for pediatric cardiopulmonary bypass Perfusion 2022 37 785 8 10.1177/02676591211027788 34142611
15 Walcƶak A Klein T Voss J et al International pediatric perfusion practice: 2016 survey results J Extra Corpor Technol 2021 53 7 26 10.1051/ject/202153007 33814602
16 Miletic KG Delius RE Walters HL III et al Prospective validation of a novel vasoactive-ventilation-renal score as a predictor of outcomes after pediatric cardiac surgery Ann Thorac Surg 2016 101 1558 63 10.1016/j.athoracsur.2015.11.006 26872731
17 Contentin L Ehrmann S Giraudeau B Heterogeneity in the definition of mechanical ventilation duration and ventilator-free days Am J Respir Crit Care Med 2014 189 998 1002 10.1164/rccm.201308-1499LE 24735035
18 Schlapbach LJ Gibbons KS Horton SB et al Effect of NITRIC oxide via cardiopulmonary bypass on ventilator-free days in young children undergoing congenital heart disease surgery: The NITRIC randomized clinical trial JAMA 2022 328 38 47 10.1001/jama.2022.9376 35759691
19 Chan A-W Tetzlaff JM Gøtzsche PC et al SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials BMJ 2013 346 e7586 e7586 10.1136/bmj.e7586 23303884
20 Moher D Hopewell S Schulz KF et al CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials BMJ 2010 340 c869 10.1136/bmj.c869 20332511
21 Jacobs ML Jacobs JP Thibault D et al Updating an empirically based tool for analyzing congenital heart surgery mortality World J Pediatr Congenit Heart Surg 2021 12 246 81 10.1177/2150135121991528 33683997
22 Kernan WN Viscoli CM Makuch RW et al Stratified randomization for clinical trials J Clin Epidemiol 1999 52 19 26 10.1016/S0895-4356(98)00138-3 9973070
23 Harris PA Taylor R Minor BL et al The REDCap consortium: Building an international community of software platform partners J Biomed Inform 2019 95 S1532-0464(19)30126-1 10.1016/j.jbi.2019.103208
24 Osthaus W Görler H Sievers J et al Bicarbonate-buffered ultrafiltration during pediatric cardiac surgery prevents electrolyte and acid-base balance disturbances Perfusion 2009 24 19 25 10.1177/0267659109106728 19567544
25 Davidson J Tong S Hancock H et al Prospective validation of the vasoactive-inotropic score and correlation to short-term outcomes in neonates and infants after cardiothoracic surgery Intensive Care Med 2012 38 1184 90 10.1007/s00134-012-2544-x 22527067
26 Paret G Ziv T Barzilai A et al Ventilation index and outcome in children with acute respiratory distress syndrome Pediatr Pulmonol 1998 26 125 8 10.1002/(SICI)1099-0496(199808)26:2<125::AID-PPUL9>3.3.CO;2-R 9727764
27 Trachsel D McCrindle BW Nakagawa S et al Oxygenation index predicts outcome in children with acute hypoxemic respiratory failure Am J Respir Crit Care Med 2005 172 206 11 10.1164/rccm.200405-625OC 15817802
